A carregar...
Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
Palbociclib is a highly selective, reversible, oral inhibitor of cyclin‐dependent kinases 4 and 6 that is approved to treat hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer. An open‐label, single‐arm, Japanese phase 2 study was conducted to investiga...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7367628/ https://ncbi.nlm.nih.gov/pubmed/32420697 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3091 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|